F. Hoffmann-La Roche Ltd: Roche launches PRAME (EPR20330) Antibody to identify PRAME protein expression in patients that may have melanoma

The PRAME (EPR20330) Antibody evaluates PRAME protein expression from patients with suspected melanoma. Understanding if the PRAME protein is expressed helps enable more informed clinical decisions and

Related Keywords

Australia ,Japan ,United States ,Sydney ,New South Wales ,Switzerland ,America ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Birgit Masjost ,Sileia Urech ,Thomas Schinecker ,Loren Kalm ,Karsten Kleine ,Nathalie Altermatt ,Genentech ,International Academy Of Pathology ,Roche Group ,World Congress ,Roche Group Media Relations ,Rabbit Monoclonal Primary Antibody ,International Academy ,Rabbit Monoclonal Primary ,Roche Benchmark ,View Universal ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Pathol Clin ,Hoffmann ,Oche ,Aunches ,Frame ,Pr20330 ,Ntibody ,Identify ,Protein ,Expression ,Patients ,Wave ,Melanoma ,